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scores for application in OA. Researchers can estimate overall
utility scores, compute QALYs, and perform cost-utility analy-
ses within a deﬁned range of uncertainty.
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FROM THE PERSPECTIVE OF PATIENTS WITH KNEE
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OBJECTIVES: To determine the extent to which health items
identiﬁed from the perspective of patients with knee osteoarthri-
tis can be linked with the ICF; and to critically evaluate the 
ICF Comprehensive and Brief Core Sets for osteoarthritis.
METHODS: Items identiﬁed from a focus group study were
linked independently by two researchers based on the 10 a priori
linking rules. Both percentage agreement and kappa statistics
were calculated to measure inter-observer agreement. Any dis-
agreements were resolved by reaching a consensus among the
researchers. The categories linked with all items were compared
with the Comprehensive Core Set for osteoarthritis, while the
categories linked with those items reported as important by over
30% of subjects within each of 3 local ethnic groups (i.e.
Chinese, Malay, and Indian) were compared with the Brief Core
Set. Both comparisons were made only at the second level of the
ICF. RESULTS: Totally 74 items were linked with 44 different
ICF categories through 105 linkages with generally very good
inter-observer agreement. The 69 items were linked with the ICF
at the third or fourth levels. Both commonalities and disparities
were found through comparison between the categories linked
with these items and both Core Sets for osteoarthritis. CON-
CLUSIONS: In this study, all items could be successfully linked
with the ICF. The ICF Comprehensive Core Set demonstrated
general conceptual validity, while the Brief Core Set needs to be
supported by more empirical evidence in various socio-cultural
contexts. This study speciﬁcally complemented the development
and reﬁnement of both Core Sets from the perspective of patients
with knee osteoarthritis.
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OBJECTIVE: The 18-item ARTS questionnaire measures 4
dimensions relative to satisfaction with osteoarthritis treatment:
Effectiveness, Convenience, Tolerability, and Medical Care.
Validity studies and discriminant properties are reported in order
to establish a clinical relevant difference in the overall score and
a satisfaction threshold. METHODS: Two samples are com-
pared: a normative group of 163 used for linguistic validation
and an unsatisﬁed group of 1750 patients derived to a more tol-
erated treatment with COX-2. Groups are compared using t-test,
ANOVA and Tukey’s HSD. Sensitivity and related ﬁgures are
estimated using the ROC curve using as criteria the patients’
need of change in treatment (judged by the clinician). RESULTS:
The normative group renders a normal distribution of scores
(65.4 + 13.4, mean + SD), slightly biased above the 0–100 scaled
mid-point. The total score mean value for the unsatisﬁed sample
(52.5 + 11.1) was signiﬁcantly lower (p < 0.001) than for the
normative group, and much lower than the satisﬁed subgroup
(76.5 + 13.9). By dimensions, the larger difference between the
satisﬁed subgroup and the rest of patients who needed change
was observed in the Effectiveness dimension (dif = 34.1, t =
11.3), followed by Convenience (dif = 27.3, t = 10.1), Tolera-
bility (dif = 26.5, t = 5.3), and Medical Care (dif = 14.0, t = 5.7).
No differences were found between genders, neither in the nor-
mative group nor in the unsatisﬁed group. Sensitivity = 72%,
speciﬁcity = 77%, positive predictive value = 89% and negative
predictive value = 53% are obtained using a cut-off point of
69.18 determined from the clinical judgment of a need of change
in treatment (threshold value). Signiﬁcance differences in mean
score are also found between groups differing in tolerance to
actual treatment. CONCLUSION: ARTS is a sensitive instru-
ment and can be used to detect differences in the patients’ satis-
faction with osteoarthritis treatment. Differences between
groups of known satisfaction level are signiﬁcant and meaning-
ful, although it should be noted that the normative mean score
is above the scale midpoint.
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OBJECTIVES: To estimate change in quality of life (QoL) in
patients with psoriatic arthritis (PsA) receiving adalimumab vs.
placebo, as measured by the health utility measurement Short
Form 6D (SF-6D). METHODS: In a placebo-controlled, Phase
III trial of adalimumab (ADEPT), patients with active PsA
received adalimumab 40mg every other week (eow) or placebo
for 24 weeks. The SF-6D was estimated at baseline, 12 weeks
and 24 weeks using responses to the Short Form 36 (SF-36)
patient questionnaire. Multiple linear regression models were
estimated to explore the effects of age, sex, disease duration, con-
comitant therapies, baseline Health Assessment Questionnaire
Disability Index (HAQ DI), and the Psoriasis Area and Severity
Index (PASI). Patients were further differentiated as responders
or non-responders using the Psoriatic Arthritis Response Crite-
ria (PsARC) and an improvement in the PASI by 75% (PASI 75).
RESULTS: Baseline SF-6D values were 0.66 and 0.65 for the
adalimumab and placebo arms respectively. Overall, adali-
mumab improved health utility by 10.6% (SD = 18.9) in com-
parison to 2.9% (SD = 16.2) for placebo. Adalimumab was
particularly efﬁcacious in patients with skin involvement (13.7%
(SD = 20.9) versus 0.5% (SD = 17.0)). PsARC response was a
signiﬁcant predictor of utility improvement, and, for patients
with skin involvement, PASI 75 was also important CONCLU-
SIONS: These ﬁndings demonstrate that adalimumab was efﬁ-
cacious in improving PsA patients’ quality of life; and this
efﬁcacy was observed to an even higher degree in patients with
more skin involvement. Health utilities, when modeled with
associated costs over a patients’ lifetime, will facilitate the eco-
nomic evaluations of adalimumab.
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OBJECTIVE: To evaluate the direct medical cost in the man-
agement of rheumatoid arthritis (RA) as well as the extent of
resource use in current practice from the perspective of public
health organization in Hong Kong. METHODS: This study was
a retrospective design. Subjects recruited must have RA diag-
nosed and attended the follow-up visits, receiving RA treatment
in the Prince of Wales Hospital (PWH) between the period of 1st
January 2002 to 31st December 2002. Data was collected by
medical chart review. The direct medical costs included inpatient
care, outpatient visits, laboratory monitoring, radiological pro-
cedure, drug cost and side effects management. RESULTS: A
total of 147 patients were included in our study. The average 
age and the duration of disease of our subjects were 54.7 years
old (SD: 10.9) and 12.6 year (SD: 7.0) respectively. The annual
direct medical cost per each RA patient was HK $18,657 (US $1
= HK $7.8). The inpatient care contributed 43.8% of the total,
which was the highest. The cost for laboratory monitoring 
was the second (19.2%) where the outpatient cost ranked the
third (15.4%). The cost for RA-related drugs accounted for
9.8%. The cost for the management of the side effects shared
3.1% of the total. Based on a local epidemiological study, the
RA prevalence rate was 0.3%. The annual direct medical cost
for the management of RA in Hong Kong would be HK $443
million, which shared 1.4% of the total health care budget in
2002. CONCLUSION: This study demonstrated that RA was a
signiﬁcant economic burden to the health care budget of Hong
Kong.
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Effective high-cost medicines, for example, tumour necrosis
factor inhibitors (TNFIs), are subsidised in Australia under the
Pharmaceutical Beneﬁts Scheme (PBS), but access is restricted to
ensure cost-effective use. An application for initial or continuing
access to TNFIs requires detailed information on each patient,
including laboratory markers and previous pharmacotherapies.
OBJECTIVES: To examine the access to TNFIs in Australia for
treating rheumatoid arthritis. METHODS: Both aggregated, and
individual de-identiﬁed information were requested from the
Health Insurance Commission (HIC) including the number of
applications received and approved, patient demographics, use
of other disease-modifying anti-rheumatic drugs, changes in clin-
ical outcomes, the time interval between application and deci-
sion to approve, and geographical pattern of usage. Prescription
and expenditure data (August 2003–March 2005) for the TNFIs,
etanercept, inﬂiximab, and adalimumab, were examined.
RESULTS: The detailed clinical information submitted with the
applications was not captured by the HIC database. A total of
19,629 prescriptions was reimbursed: etanercept (15,675), inﬂix-
imab (570), and adalimumab (3384), at a total cost of
AUD$43.5 million. The uptake of these agents was considerably
lower than expected. The number of patients using a TNFI under
the PBS could only be approximated from these aggregated
ﬁgures—more than 2,000 patients had been commenced on
TNFIs. The proportion of patients that were approved to 
continue or switch between TNFIs was not available. CON-
CLUSION: The HIC is positioned to capture subsidised pre-
scription-drug usage and clinical outcome data on a national
basis. Unfortunately, it is impossible to access detailed data.
Information on utilisation of TNFIs is far from adequate. Com-
prehensive drug usage and patient health outcome data need to
be accessible in order to deﬁne the most appropriate use and
access to these agents. Update of, and arrangements for access
to the HIC database are encouraged.
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Access to high-cost medicines such as to the tumour necrosis
factor inhibitors (TNFIs) for the treatment of rheumatoid arthri-
tis is tightly regulated under Australia’s Pharmaceutical Beneﬁts
Scheme (PBS) to ensure their cost-effective use. OBJECTIVES:
To explore stakeholders’ perceptions and experiences associated
with the restricted access to TNFIs and the process of collabo-
ration between key stakeholders who formulated the access 
criteria. METHODS: Thirty-three, in-depth semi-structured
interviews were conducted between 2004 and 2005. Participants
included rheumatologists, patients treated with TNFIs, consumer
representatives, government health advisors, public servants, and
representatives from pharmaceutical companies involved in for-
mulating and implementing the access restrictions. Participants
were asked to comment on the access restrictions that have
applied since August 2003, and their views on the collaboration
between stakeholders were collected. Interviews were recorded,
transcribed verbatim, and thematically analysed. RESULTS: The
principle of “controlled access” to TNFIs was in general
accepted by all, despite the different perspectives each person
represented. However, there were concerns regarding some of the
speciﬁc PBS criteria. Overall, the collaborative approach that
was taken to formulate the criteria for access to TNFIs was per-
ceived by key stakeholders as a valuable advance and has set a
new paradigm for subsequent PBS subsidy decisions. However,
a wider and more transparent decision-making process, and a
more structured and continuing communication between stake-
holders were judged desirable. Some degree of ﬂexibility with
respect to physician prescribing, and a need to increase educa-
tion to health care professionals and the community were pro-
posed. CONCLUSION: Targeting access to high-cost medicines
through a national subsidy system was agreed to be practical and
equitable. Increased transparency, communication and education
were identiﬁed as the main elements needed to secure support of
the ﬁnal access criteria by all involved. In order to conﬁrm these
primary themes, further interviews are being undertaken until
data saturation is achieved.
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Data from randomized controlled trials (RCTs) are often used in
economic evaluations when estimating cost-effectiveness. The
data generated from RCTs represent ideal experimental condi-
tions (efﬁcacy) and the applicability of this data to real world
settings (effectiveness) may be questionable. OBJECTIVES: 1) To
conduct an economic evaluation of etanercept (a competitive
inhibitor of TNF-a) use in rheumatoid arthritis patients in
Canada, and 2) To compare the results of a cost-effectiveness
analysis conducted with efﬁcacy data obtained from a RCT, to
results derived by using effectiveness data obtained from com-
munity-based clinical practice. METHODS: The data used to
perform the analyses were obtained from a trans Canadian com-
munity-based cohort study conducted between 1999 and 2003.
A cost-utility analysis was preformed and incremental cost-effec-
